Page 2 of 2
12

2007 (3 POSTS)

Perry CS. Vibrios in surface waters and a hypothetical scenario using EPA’s Environmental Consequence Assessment Tool (ECAT). Society for Risk Analysis Annual Meeting, San Antonio, TX, December 2007.

Smith JD, Perry C, Garcia S. Jenkins A, Dwyer M, Garrahan K. Emergency Consequence Assessment Tool (ECAT) for USEPA NHSRC. Society for Risk Analysis Annual Meeting, San Antonio, TX, December 2007.

2006 (1 POST)

Finster M, MacDonell M, Bhattacharyya M, Haroun L, Peterson J, Perry C. Environmental fate and cumulative risk context for cleanup programs. Society for Risk Analysis Annual Meeting. Baltimore, MD, December 2006.

2005 (1 POST)

Perry CS, Garcia S, Collie S, MacDonell M, Adeshina F, Sonich-Mullin C. Application of provisional advisory levels for EPA National Homeland Security Research Center’s secure, internet-based rapid risk tool. Society for Risk Analysis’ Annual Meeting, Orlando, FL, December 2005.

2004 (1 POST)

Perry CS, Morton E. Lessons learned from creating integrated Excel models to calculate human health screening values. Society for Risk Analysis Annual Meeting, Palm Springs, CA, December 2004.

2003 (1 POST)

Perry CS. Process for development of protective concentration levels for remediation sites in Texas. Presented at Society for Environmental Toxicology and Chemistry (SETAC) meeting, Austin, TX, November 2003.

2002 (1 POST)

Perry CS. TRRP Rule – The basics part 2: Human health PCLs and look-up tables. TNRCC Environmental Trade Fair presentation and paper, 2002.

1996 (2 POSTS)

Ramu K, Perry CS, Ahmed T, Pakenham G, and Kehrer JP. 1996. Studies on the basis for the toxicity of acrolein mercapturates. Toxicol Appl Pharmacol 140(2):487-498; doi: 10.1006/taap.1996.0245.

View Abstract

Sauers L and Perry C. 1996. Regulatory affairs – A growing opportunity for toxicologists. SOT Communiqué, May/June 1996.

1995 (1 POST)

Perry CS, Liu XL, Lund LG, Kehrer JP. 1995. Differential toxicities of cyclophosphamide and its glutathione metabolites to A549 cells. Toxicol in Vitro 9(1):21-26; doi: 10.1016/0887-2333(94)00187-Y.

View Abstract
Page 2 of 2
12